Prolyl oligopeptidase (PREP) is an abundant peptidase in the brain and periphery, but its physiological functions are still largely unknown. Recent findings point to a role for PREP in inflammatory processes. This study assessed the cellular and extracellular PREP activities in cultures of mouse primary cortical neurons, microglial cells and astrocytes, and immortalized microglial BV-2 cells under neuroinflammatory conditions induced by lipopolysaccharide (LPS) and interferon gamma (IFNγ). Furthermore, we evaluated the neuroprotective effect of a specific PREP inhibitor, KYP-2047, in a neuroinflammation model based on a coculture of primary cortical neurons and activated BV-2 cells. The inflammatory insult reduced intracellular and increased extracellular PREP activity specifically in microglial cells, suggesting that activated microglia excretes active PREP. A targeted proteomics approach revealed up-regulation in PREP protein levels in BV-2 cell growth medium but down-regulation in crude membrane-bound PREP after LPS+IFNγ. In the coculture of BV-2 cells and primary neurons, an increase in extracellular PREP activity was also detected after inflammation. KYP-2047 (10 μmol/L) significantly protected neurons against microglial toxicity and reduced the levels of the pro-inflammatory cytokine tumour necrosis factor alpha.
market to date, probably due to a lack of efficacy as well as an incomplete understanding about the physiological functions of this enzyme. Nevertheless, several potential functions for PREP have been proposed over the last decade; it may be involved in α-synuclein aggregation in Parkinson's disease, 6, 7 in angiogenesis 8 and in inflammatory responses. 9 ,10 PREP has also been associated with neurodegenerative processes, as post-mortem brain PREP activity has been observed to be altered in several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis.
11
Microglia are resident immune cells in the CNS having wide variety of physiological functions, for example tissue surveillance and synaptic remodelling. The acute inflammatory microglia activation has been suggested to promote clearance of pathogens and cellular debris and restore tissue homeostasis. 12 However, chronic activation of microglia is harmful to the CNS and there is a convincing body of evidence pointing to a role for neuroinflammation in the pathogenesis of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. [13] [14] [15] Microglia activation results in a flooding of surrounding tissue with inflammatory mediators, oxidizing free radicals, pro-apoptotic factors, matrix-degrading proteases and chemoattractant molecules. 16 All of these activities contribute to the inflammatory process. As neuroinflammation has been closely associated with neurodegenerative pathways, [13] [14] [15] antiinflammatory compounds may be potential disease-modifying treatment options for neurodegenerative diseases. Interestingly, there is now an extensive literature focused around the theme of PREP and neuroinflammation. The expression of PREP protein in mouse brain has been demonstrated to be elevated in microglial cells and astrocytes after an inflammatory insult. 10 Furthermore, PREP knockout mice were resistant to the microglia-activating effect of lipopolysaccharide (LPS) treatment. 17 Brain PREP levels were significantly elevated in an in vivo rat model of neuroinflammation, and notably, in rats experiencing neuroinflammation, a microdialysis approach revealed increased PREP activity in the brain extracellular space, 18 although under normal conditions, the enzyme is known to be mainly cytosolic. 19, 20 The origin of this extracellular PREP activity remains unclear, nor is it known why it is excreted into the extracellular space in inflammatory conditions. Elevated extracellular PREP activity has also been detected from different body fluids in diseases with an inflammatory component, including several forms of cancer, [21] [22] [23] cystic fibrosis 9 and rheumatoid arthritis, 24 hinting at a role for extracellular PREP in the remodelling of tissues at sites of inflammation. Moreover, PREP enzymatic activity has been recently associated with cleavage of extracellular matrix components. 9, 25 Although the contribution of PREP to the development of peripheral or neuronal inflammation is not well understood, one could postulate a specific extracellular role for PREP in the inflammatory process. Furthermore, it remains to be clarified whether specific PREP inhibitors have anti-inflammatory or neuroprotective properties in central nervous system (CNS) diseases with an inflammatory component. To shed light on the behaviour of PREP in neuroinflammatory conditions, we investigated the intra-and extracellular PREP enzymatic activities under LPS and interferon gamma (IFNγ)-induced inflammation in cultures of mouse primary cortical neurons, microglial cells and astrocytes, and immortalized microglial BV-2 cells. We hypothesized that activated microglia might be the source of the extracellular PREP activity observed in previous studies. Furthermore, we assessed the neuroprotective effect of a specific PREP inhibitor, KYP-2047, in an in vitro model of neuroinflammation based on a coculture of primary cortical neurons and microglial BV-2 cells activated with LPS and IFNγ.
| MATERIALS AND METHODS

| Ethical statement
The experimental procedures involving animals (primary cell harvest) were made in compliance with the European Commission Directive 2010/63/EU and approved by the Institutional Animal Care and Use Committee of University of Eastern Finland (Animal Usage Plan numbers: EKS-008-2016 and EKS-006-2017). All efforts were made to minimize the number of animals used and to minimize their suffering.
| BV-2 cell cultures
Immortalized mouse microglial BV-2 cells were grown in RPMI-1640 medium (Sigma, St. Louis, MO, USA) supplemented with 10% foetal bovine serum (FBS, Gibco, Thermo Fisher Scientific, Waltham, MA, USA), 2 mmol/L L-glutamine (Lonza, Basel, Switzerland) and 1% penicillin-streptomycin (P/S: 100 U/mL penicillin and 100 U/ mL streptomycin, Lonza) in 15-cm cell culture plates (Nunc) as previously described. 26 In the PREP activity measurement,~4 x 10 5 cells were plated/well in 6-well plates in Neurobasal TM medium (Gibco) supplemented with 2% B27, 2 mmol/L L-glutamine and 1% P/S. After 2 hours, inflammation was induced by addition of 200 ng/mL LPS (Sigma) and 20 ng/mL of mouse IFNγ (Sigma). After 48 hours, medium samples were collected and cultures were rinsed twice with ice-cold phosphate-buffered saline (PBS) (DPBS, Lonza) on ice. Cells were scraped in 100 μL of T-Per (Thermo Scientific, Waltham, MA, USA) and incubated on ice for 30 minutes. The lysates were centrifuged at 10 000× g, 10 minutes, at +4°C, and supernatants were collected to new tubes for PREP activity assays. In the targeted PREP proteomics assay,~10 6 cells were plated in 10-cm dishes and treated similarly as the samples in the PREP activity measurement. After 48 hours, cells were washed three times with PBS, scraped into icecold PBS followed by centrifugation of the cells into a pellet and rapid freezing in liquid nitrogen.
| Mouse primary microglia and astrocyte cultures
Neonatal (P0-P2, mixed gender) C57BL/6 WT mice were supplied by the Laboratory Animal Center of the University of Eastern Finland, Kuopio, Finland. The mice were housed in stainless steel cages and kept on a 12-hour light/12-hour dark cycle at an ambient temperature of 22°C. The pups were rapidly decapitated, and the brains were dissected and meninges were removed. Brain tissue was dissociated using mechanical shearing and trypsin. Cells of two brains were plated on poly-L-lysine (Sigma)-coated T75 culture flasks and cultured in Dulbecco's modified Eagle's medium (DMEM, Lonza) supplemented with 10% FBS (Gibco), 2 mmol/L L-glutamine (Lonza) and 1% P/S (Lonza). On the next day, the cells were washed three times with PBS (DPBS, Lonza) to remove cellular debris and cultured with DMEM supplemented with 10% FBS, 2 mmol/L L-glutamine (Lonza) and 1% P/S (Lonza). After 7 days, mature microglia were shaken off from the astrocytic monolayer. Microglia were cultured in DMEM (with 10% FBS, 2 mmol/L L-glutamine and 1% P/S). The remaining astrocytic monolayer was trypsinized using 0.05% trypsin-ethylenediaminetetraacetic acid (EDTA) (Gibco). Astrocytes were cultured in 15-cm dishes in F12/ DMEM (Gibco) supplemented with 2 mmol/L L-glutamine and 1-% P/S and subcultured until passage 4-5 to remove any microglial cells. In the PREP activity measurement, both primary microglia and astrocytes were treated with LPS and IFNγ for 48 hours and the medium samples and cell lysates were collected similarly as in BV-2 cells. The purities of the primary microglial and primary astrocytic cultures were investigated by immunofluorescence staining. Cd11b monoclonal rat primary antibody (1:300; AbD Serotec, Kidlington, UK) and Alexa Fluor 594 anti-rat secondary antibody (1:500; Abcam, Cambridge, UK) were used for primary microglial cultures. Nuclei of the cells were stained with 4′,6-diamidino-2-phenylindole (DAPI) (1 μg/mL; Sigma). A representative image ( Figure S1A) 
| Mouse primary cortical neuron cultures
Primary cortical cultures were prepared as previously described in studies published by our group. 27, 28 Briefly, on embryonic day 18 (E18), pregnant C57BL/6 mice (age 4-6 months, Laboratory Animal Center of the University of Eastern Finland) were killed by cervical dislocation. Unborn pups were killed by rapid decapitation. Cortical brain tissues were dissected under the microscope, and cells were harvested as described previously. 27 Cells pooled together from different embryos were plated (18 × 104/cm 2 ) on poly-D-lysine (PDL)-coated wells in 6-well or 48-well plates in serum-free Neurobasal medium (Gibco, Invitrogen) supplemented with 1× B27 (Gibco), 2 mmol/L L-glutamine (Lonza) and 1% P/S (Lonza). Half of the medium was refreshed after 4 days in vitro (DIV4).
In the measurement of PREP activity, cells were treated at DIV5 with LPS and IFNγ (200 and 20 ng/mL, respectively), and samples were collected at DIV7 similarly as in BV-2 cells. We have characterized these primary neuronal cultures in detail in our previous studies 28 and identified that, at DIV7, the cultures contain 80% of microtubuleassociated protein 2 (MAP2)-positive cells, 12-% of GFAP-positive astrocytes and 8% of other cell types. We also confirmed by Western blotting that LPS-IFNγ treatment does not induce astrocytosis in primary neurons nor in the coculture of neurons and BV-2 cells as indicated by unchanged GFAP levels after treatment (data not shown).
| Mouse primary cortical neuron and BV-2 cell coculture
The neuroprotective effect of KYP-2047 was assessed in a coculture of primary neurons and BV-2 microglial cells. This coculture model was established based on the method described by Gresa-Arribas et al 26 with minor modifications. Preparation and characterization of the cocultures have been described previously. [26] [27] [28] Briefly, mouse cortical neurons for the cocultures were isolated and cultured in 48-well plates as described above. BV-2 microglial cells were seeded at a 1:5 ratio onto the primary cortical cultures on DIV5. The anti-inflammatory cytokine, interleukin 10 (IL-10, 50 ng/mL, Peprotech) and the inducible nitric oxide synthase ( and a long (4.8 hours) enzyme-inhibitor complex dissociation half-life. 29 PREP inhibitor concentrations in the viability assay were estimated based on our in vivo studies, where the C max value of unbound KYP-2047 in brain extracellular fluid reached a level of approximately 1 μmol/L after a single dose, a concentration that effectively inhibited rat brain PREP. 32 
| Viability assay
Neuronal viability in the mouse primary cortical neuron and BV-2 microglial cocultures was assessed as described earlier. 26 Briefly, wells were rinsed twice with PBS to remove any dead cells. The cells were fixed in 4% paraformaldehyde in PBS for 20 minutes and then incubated in 0.3% hydrogen peroxide in methanol to permeabilize the cells and block endogenous peroxidase activity. Incubation in blocking solution containing 1% bovine serum albumin and 10% horse serum for 20 minutes was used to prevent non-specific staining. Neurons were stained by incubation with mouse anti-MAP2 primary antibody (1:2000, Sigma) overnight at +4°C. Next, the cells were incubated with biotinylated horse anti-mouse secondary antibody (1:500, Vector Labs, Burlingame, CA, USA) for 1 hour and ExtrAvidin-horseradish peroxidase (HRP) (1:500, Sigma) for another 1 hour. The cells were washed three times for 10 minutes in PBS between the antibody incubations. All antibody dilutions were made in the blocking solution. Finally, 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) peroxidase substrate solution (Vector Labs) was prepared following the manufacturer's instructions and added onto the cells. The absorbance was measured using a microtitre plate reader (ELx808, BioTek or Infinite M200, Tecan, Männedorf, Switzerland) at 405 nm and was directly proportional to the number of neurons in the wells. The measured background absorbance from cocultures incubated without the anti-MAP2 primary antibody (negative controls) was averaged and subtracted from the absorbances in the other wells. The absorbance in the negative control wells was similar to the absorbance measured from wells without any cells. To assess the effect of KYP-2047 on neuronal viability, altogether 15-21 samples/treatment from three individual experiments were measured.
| LDH assay
Cytotoxicity Detection Kit (LDH) (Roche) was used to reveal any possible cytotoxicity of LPS and IFNγ or KYP-2047 treatment in BV-2 cells. Medium samples (50 μL) from the cell cultures were used to assess the cytotoxicity according to the manufacturer's protocol. Absorbance was measured at 450 nm with a microplate reader.
| TNF-α and NO measurements
Mouse tumour necrosis factor alpha (TNF-α) ELISA Ready-SET-Go! Kit (Affymetrix, San Diego, CA) was used for the detection of TNF-α in the conditioned media. Nitric oxide (NO) levels were determined using the Griess Reagent Kit for nitrite determination (G-7921, Life Technologies, Thermo Fisher Scientific). All kits were used as recommended by the manufacturers.
| Prolyl oligopeptidase activity measurement
Prolyl oligopeptidase activity in cell culture and cell growth medium was measured fluorometrically using SucGly-Pro-7-Amino-4-methylcoumarin (AMC) (Bachem AG, Switzerland) as the substrate for PREP. Briefly, cell medium was first concentrated from 3 mL down to 100 μL using a centrifugal filter device (Amicon Ultra, molecular weight cut-off 30 kDa, Millipore Corporation, Billerica, MA) and a Heraeus Minifuge (4000× g, 20 minutes, +4°C). To accomplish buffer exchange, the remaining ultrafiltrate was reconstituted to the original sample volume with 0.1 mol/L Na-K-phosphate buffer (incubation buffer) and centrifuged again to 100 μL (4000× g, 20 minutes, +4°C). Aliquots of 10 μL of the cell medium ultrafiltrates or cell lysates collected as described above were used in the PREP activity assays. The samples were pre-incubated for 30 minutes with 70 μL of incubation buffer at 32°C in 96-well plates, and the enzyme reaction was initiated by adding 20 μL of 4 mmol/L Suc-Gly-Pro-AMC. The plates were incubated for 180 minutes at 32°C, until the reaction was terminated by addition of 100 μL of 1 mol/L sodium acetate buffer (pH 4.0). (Table S1 ) derived from a stable isotopelabelled peptide and the unlabelled natural peptide.
| Statistical analysis
The number 'n' indicates the number of independent observations with different cell cultures and experimental conditions. Results in the text are expressed as mean ± standard deviation and in the figures as box and whiskers plots representing the median and the value of the highest and lowest observation. Statistical analyses were performed with GraphPad Prism 5.03 software (GraphPad Software, San Diego, CA) or SPSS Statistics (IBM SPSS Statistics for Windows, version 21.0. Armonk, NY, IBM Corp.). Differences in PREP activities and protein levels between untreated and LPS+IFNγ-treated groups were tested using unpaired two-sample two-tailed Student's t test (GraphPad Prism). The effects of different concentrations of KYP-2047 on neuronal viability and TNF-α levels were tested with one-way analysis of variance (ANOVA) followed by least significant difference (LSD) post hoc test (SPSS). For the variance analyses, the normal distribution of the data was tested with Shapiro-Wilk's W test and the homogeneity of variances with Levene's test (SPSS). Outliers were tested by Grubb's test using online tools provided by GraphPad Software (https://www.graphpad.com/quickcalcs/grubbs2/). No data were excluded from the analyses. The criterion for statistical significance was set at P < 0.05.
| RESULTS
| Prolyl oligopeptidase enzymatic activity in different cell types and in cell culture mediums
Firstly, we investigated the cellular PREP enzymatic activities from untreated mouse primary neurons, primary microglial cells, primary astrocytes and microglial BV-2 cells ( Figure 1A-D) . The highest cellular PREP activity was detected in the primary neurons (4.8 ± 1.4 nmol/min/mg) followed by BV-2 cells (4.7 ± 1.7 nmol/min/mg), primary astrocytes (3.2 ± 0.14 nmol/min/mg) and primary microglia (1.3 ± 0.06 nmol/min/mg). Next, we stimulated the cells with a combination of LPS and IFNγ. In primary neurons, there was a small non-significant decrease (to 4.2 ± 2.3 nmol/min/mg) in PREP activity after LPS+IFNγ treatment. Instead, in primary microglial cells and in BV-2 cells, LPS and IFNγ stimulation significantly reduced cellular PREP activity by 23% (to 1.0 ± 0.1 nmol/min/mg; t test: P = 0.0158) and 57% (to 2.0 ± 0.7 nmol/min/mg; t test: P = 0.0006), respectively. Notably, in primary astrocytes, LPS and IFNγ induced a significant 46% increase (to 4.6 ± 0.2 nmol/min/mg; t test: P = 0.0006) in PREP activity compared to untreated astrocytes. Next, we measured PREP activity in a coculture of primary neurons and BV-2 cells with and without the presence of LPS and IFNγ ( Figure 1E) ; the inflammatory stimulus reduced PREP activity by 17%, but the difference from the untreated coculture was statistically non-significant (4.7 ± 3.4 vs 3.9 ± 2.5 nmol/min/mg in untreated and stimulated cocultures, respectively).
Based on the findings of reduced cellular PREP activities, we have been suggested that the microglial PREP enzyme activity had been excreted into the extracellular space after the neuroinflammatory stimulus. Thus, we measured PREP activities from the cell culture mediums with and without LPS and IFNγ (Figure 2A-E) . Indeed, in primary microglial and BV-2 cultures, we were able to detect significant amounts of PREP enzymatic activity, and the activities were significantly up-regulated after the inflammatory stimulus. Overall, the extracellular activities were low compared to the cellular activities (in the picomolar range vs nanomolar in cells). In BV-2 cells, there was a 3.5-fold increase (from 199 ± 68 to 709 ± 181 pmol/min/ mg; t test P = 0.0103) in the extracellular activity after LPS and IFNγ stimulation. In primary microglia, the extracellular PREP activities were low, but LPS and IFNγ treatment induced a significant sevenfold increase (from 2.6 ± 1.2 to 18 ± 1.3 pmol/min/mg; t test: P = 0.0001) in the extracellular activity. In primary neurons and astrocytes, we found no detectable PREP activities in the cell culture mediums. Instead, in a coculture of primary neurons and BV-2 cells, LPS and IFNγ significantly up-regulated extracellular PREP activity by 2.6 times (from 18.7 ± 4.1 to 49 ± 15 pmol/min/mg; t test: P = 0.0305). Importantly, based on an LDH cytotoxicity assay, LPS and IFNγ treatment did not induce any significant cell death in BV-2 cell cultures as compared to control treatment (see Figure S3A ), indicating that PREP was not released to the extracellular space because of microglial cell damage. Next, to clarify the origin of the extracellular PREP at cellular level, we investigated the PREP protein levels from the cytosolic and crude membrane fractions of the BV-2 cells. In addition, we wanted to confirm that the measured extracellular PREP activity was indeed attributable to PREP protein. For these purposes, we set up a targeted LC-MS/MS proteomics assay for detection of PREP protein from crude membrane and cytosol as well as from cell medium with and without LPS+IFNγ-induced inflammation. PREP protein was present in both investigated cell fractions and in the cell medium (see Figure S2 for representative chromatogram). Interestingly, the inflammatory stimulus induced a significant decrease in crude membranebound PREP protein levels (from 0.49 ± 0.03 to 0.35 ± 0.02 fmol/μg protein; t test: P = 0.0033) (Figure 3A) , whereas there was a trend towards increased PREP levels in the cytosolic fraction (from 1.83 ± 1.19 to 2.90 ± 0.89 fmol/μg protein) ( Figure 3B ) and a significant 2.5-fold increase in the extracellular PREP protein concentrations (from 0.04 ± 0.02 to 0.10 ± 0.02 fmol/μg protein; t test: P = 0.0132) in the LPS+IFNγ-treated cells compared to control cells. Finally, a specific PREP inhibitor assay control (KYP-2047 at 1 μmol/L concentration) was included to every PREP activity assay to confirm that the formed AMC resulted from PREP enzymatic activity. By this approach, we controlled that the substrate is not cleaved by some other peptidase in these experimental conditions. The results confirmed (data not shown) that the AMC production could be completely blocked by KYP-2047, confirming that the detected activities were indeed a result of functional PREP enzymatic activity.
| The effect of Prolyl oligopeptidase inhibition on neuronal viability and TNF-α levels
Next, we hypothesized that the extracellular PREP derived from activated microglia might contribute to microglial toxicity and thus could be a potential target for neuroprotection. Thus, we performed a pharmacological PREP inhibitor study in a coculture model of mouse primary neurons and BV-2 cells. The detailed characteristics of the model have been published by Martiskainen et al 28 BV-2 cells were added to the mouse cortical neuron cultures after 5 DIV at the ratio 1:5, and neuroinflammation was induced using LPS and IFNγ. Activated BV-2 cells secrete proinflammatory cytokines and nitric oxide and induced a significant 50% decrease in neuronal viability as compared to vehicle-treated samples (LSD post hoc: P < 0.001 No LPS+IFNγ vs control, Figure 4A ). Positive controls IL-10 and 1400 W worked as described previously. Figure 4B ). There was also a trend towards decreased NO levels with all KYP-2047 concentrations (data not shown). However, this decrease was not statistically significant. We also confirmed by an LDH cytotoxicity assay that KYP-2047 at 10 μmol/L concentration was not cytotoxic to BV-2 cells (see Figure S3B ).
| DISCUSSION
Using the targeted proteomics approach and functional enzyme activity assay, we demonstrated that microglial BV-2 cells contain both PREP protein and enzyme activity. When primary or immortalized microglial cells were stimulated with LPS and IFNγ, the cellular PREP activities decreased and the extracellular activities increased, suggesting that the microglial cells excrete active PREP into the extracellular space upon inflammation. Instead, in primary neurons and astrocytes, PREP activity remained intracellular and was even up-regulated in astrocytes in response to the inflammatory stimulus. However, the results obtained with the primary astrocytes should be interpreted with caution, because our immunofluorescence staining revealed that the astrocyte cultures, unlike the primary microglial cultures, contained some contaminating cell types. In a coculture of primary neurons and BV-2 cells, a significant increase in extracellular PREP activity was observed upon inflammation, implying that activated microglia had been the source for the extracellular activity also in the coculture. Notably, extracellular PREP activity in pmol/min/mg appeared to be much lower in the coculture than in the BV-2 cells simply because the activity was normalized to the total protein content of the corresponding cell lysate, and a large portion of the total protein in the coculture is from the neurons that do not excrete PREP into the extracellular space, thus diluting the activity. The mechanism by which microglial cells extrude active PREP into the extracellular space is unclear as its protein sequence lacks the signal peptides associated with secretory pathways. Interestingly, crude membrane-bound PREP protein levels in BV-2 cells decreased during inflammation, making it tempting to speculate that the increased extracellular activity is actually released from the membrane-bound form of PREP. Indeed, it has been postulated that the membrane-bound PREP is merely a transitory stage needed for the transportation of cytosolic PREP out of the cell. 35 Extracellular PREP activity has been detected in various human body fluids, although the activities have been low compared to the cellular levels 21 as also observed in the present study. Interestingly, elevations in human plasma PREP activities have been associated with several pathological conditions involving an inflammatory component, such as schizophrenia and depression. 36 Elevated PREP activity has also been detected in the sputum of cystic fibrosis patients 9 and knee synovial fluid of patients with rheumatoid arthritis. 24 Pre-clinically, extracellular brain PREP activity has been identified in a rat model of neuroinflammation. 18 Thus, the present study raises the possibility that the increased extracellular PREP activity observed in these pathological conditions did originate from the immune cells at the site of inflammation. It remains to be clarified why extracellular PREP activity increases specifically in microglial cells during inflammation, but PREP appears to play a role in microglia activation, as PREP knockout mice show a lack of response to LPS at both behavioural and immunohistochemical levels. 17 Furthermore, extracellular PREP has been associated with the cleavage of extracellular matrix components, such as collagen 9,37 and neural cell adhesion molecule (NCAM). 25 PREP overexpression in SH-SY5Y cells selectively activates matrix metalloprotease 9 (MMP-9), a key player in the extracellular matrix remodelling. The extracellular location of PREP upon neuroinflammation may also promote the extracellular cleavage of the classical PREP substrates, such as substance P, neurotensin, arginine vasopressin and bradykinin, 1 and PREP inhibitors might protect these peptides against cleavage and increase their brain levels in pathological conditions involving an inflammatory component. Since PREP appears to have specific extracellular functions during inflammation that may be related to extracellular matrix remodeling, we hypothesized that specific PREP inhibitors might have neuroprotective effects upon neuroinflammatory stimulus. We tested this hypothesis in a coculture of mouse primary neurons and microglial BV-2 cells treated with a specific PREP inhibitor, KYP-2047. Interestingly, we observed a trend towards dose-dependent increase in neuronal viability after KYP-2047 treatment, evidence of a potential neuroprotective effect for PREP inhibitors. Notably, KYP-2047 at 10-μmol/L concentration was not cytotoxic to BV-2 cells, implicating that the reduced TNF-α secretion by KYP-2047 was not due to a reduction in BV-2 cells. Neuroprotection might be explained by an anti-inflammatory effect, as was preliminary demonstrated by decreased TNF-α levels after KYP-2047 treatment. However, to confirm the anti-inflammatory effect, future research should be undertaken to investigate the effect of PREP inhibition on multiple cytokine production in microglial cells. The neuroprotective effects are in agreement with the findings of Klegeris et al, 38 who reported an increase in the extracellular PREP activity in THP-1 monocytic cells after stimulation with LPS and IFNγ, and a partial neuroprotective effect with two PREP inhibitors. KYP-2047 readily penetrates the cell membranes and reaches the intracellular PREP, 32 and thus, it remains to be clarified with a non-cell membrane-permeable PREP inhibitor whether the anti-inflammatory effect is dependent upon the inhibition of intra-or extracellular PREP. In summary, these results further support the idea that PREP inhibitors have potential as neuroprotective compounds in a heightened neuroinflammatory environment, possibly by regulating the activity of extracellular matrixdegrading proteases such as MMP-9. 25 However, further studies will be needed to investigate the effects of PREP inhibition on extracellular matrix degradation.
In conclusion, PREP enzymatic activity and protein levels in microglial cells are increased in the extracellular space after an inflammatory insult, suggesting an extracellular role for PREP in the inflammatory process. A PREP inhibitor protects primary neurons against the toxicity of activated microglia and exerts anti-inflammatory effects via reduced TNF-α levels. The exact mechanism of action of neuroprotection remains to be clarified and will require further testing of PREP inhibitors in in vivo models of neuroinflammation and microglial activation. These results indicate that PREP inhibitors may offer a novel therapeutic approach for the treatment of neurodegenerative disorders with an inflammatory component including Parkinson's and Alzheimer's diseases.
